Bio-Technology General - BTGC- Profile

Bio-Technology General Corp. The Group's principal activity is to conduct research, development, manufacture and marketing of biopharmaceutical products. The Group through the internal research, development and agreement has a portfolio of therapeutic products. The products include OXANDRIN (r), BIO-TROPINTM, BIOLON (r), DELATESTRYL (r), MIRCETTE (r) and others. OXANDRIN(R) is used for the treatment of weight loss due to severe trauma, chronic inflection, extensive surgery or unknown pathophysiology. BIO-TROPIN(TM) for the treatment of growth hormone deficiency in children or turner syndrome. BIOLON (R) is used for the protection of the corneal endothelium during ophthalmic surgery. DELATESTRYL (R), for the treatment of hypogonadism and delayed puberty. On 30-Sep-2002, it acquired Rosemont Pharmaceuticals Ltd. During the year 2001, the Group acquired Myelos Corporation. Product sales accounted for 97% of 2002 revenues; Contract fees, 2% and Other revenues, 1%.